

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA, MIAMI DIVISION

IN RE TERAZOSIN HYDROCHLORIDE
ANTITRUST LITIGATION

Master File No. 99-MDL-1317
MDL No. 1317

**SUMMARY NOTICE OF PENDING CLASS ACTION
PROPOSED SETTLEMENT AND FAIRNESS HEARING**

THIS NOTICE MAY AFFECT YOUR LEGAL RIGHTS. PLEASE READ CAREFULLY.

TO: ALL PERSONS AND ENTITIES WHO, OR WHICH HAVE, AT ANY TIME FROM OCTOBER 15, 1995 THROUGH MARCH 7, 2005 (THE "CLASS PERIOD") PAID ALL OR PART OF THE PURCHASE PRICE OF HYTRIN® OR ITS AB-RATED GENERIC BIOEQUIVALENTS ("TERAZOSIN PRODUCTS") INCLUDING ALL FORMS OF TERAZOSIN HYDROCHLORIDE, OTHER THAN FOR RESALE, IN AL, CA, FL, IL, KS, ME, MI, MN, MS, NV, NM, NY, NC, ND, SD, TN, WV or WI, OR VIA MAIL ORDER FOR RESIDENTS OF SUCH STATES.

This Summary Notice is to inform you of the proposed Settlement of class action lawsuits brought by Consumers, Third Party Payers ("TPPs") and the Attorneys General of Florida, Kansas, and Colorado ("Plaintiff States"), and to inform members of the proposed Settlement classes of their rights. This Notice is only a summary. **To obtain the full Notice, read the last section below.** The proposed Settlement provides for a fund that will initially contain a total of \$30.7 million. As described in more detail in the full Notice, the Settlement amount, less court-awarded attorneys' fees and expenses, incentive payments to class representatives, \$2 million allocated to the Plaintiff States, and notice and administrative costs for the Settlement, will be allocated as follows: 25% to Consumers ("Consumer Settlement Fund") and 75% to Third Party Payers ("TPPs") ("TPP Settlement Fund"). (TPPs include entities such as health insurers and employer health benefit plans that paid for Terazosin Products during the Class Period.) Notice and claims administration costs and incentive payments for Consumer and TPP Plaintiffs awarded by the Court will also be paid from these Settlement Funds. The Plaintiff States and the private Plaintiffs bringing this lawsuit each have concluded on the basis of their extensive economic, factual and legal investigation that the proposed Settlement is fair, reasonable, and adequate. The proposed Settlement is subject to approval by the Court.

The Settlement classes include all members of the classes certified by the Court in an April 8, 2004 Order, and in an additional Order on March 7, 2005 - All persons and entities who, or which have, at any time from October 15, 1995 to March 7, 2005, paid all or part of the purchase price of Terazosin Products, other than for resale, in one or more of the following states - AL, CA, FL, IL, KS, ME, MI, MN, MS, NV, NM, NY, NC, ND, SD, TN, WV or WI - or via mail order for delivery to one or more of those same states. There are exclusions from the Settlement classes for certain persons and entities, which are explained in the full Notice.

Plaintiffs filed lawsuits between 1999 and 2001 alleging that Abbott Laboratories and Geneva Pharmaceuticals, Inc. (now known as Sandoz Inc.) (the "Defendants") allegedly violated antitrust and consumer protection laws through conduct relating to the sale of Terazosin Products. Defendants deny Plaintiffs' claims and do not admit any wrongdoing by entering into this settlement. This litigation does not involve the safety or effectiveness of Terazosin Products.

If you are a member of the Settlement classes, you may have a right to share in either the TPP or Consumer Settlement Fund, if this Settlement is approved by the Court. The proposed Settlement also includes a release of claims as further described in the full Notice. If you are a TPP member of the Settlement classes, you **MUST** mail a TPP Claim Form by **July 15, 2005**, to participate in the Settlement. A TPP that wishes to be excluded from the Settlement classes **MUST** mail a TPP Exclusion Form, in compliance with the full Notice, so that it is **received** by the Settlement Administrator by **April 11, 2005**. Any TPP objecting to the Settlement **MUST** also submit objections by **April 11, 2005**, in compliance with the full Notice. If you are a Consumer member of the Settlement classes, you may exclude yourself or object to the Settlement by **June 15, 2005**, or you may file a Consumer Claim Form by **July 15, 2005**, in compliance with the full Notice. The Court has scheduled a final approval hearing to be held at 10 a.m., Eastern time, on **June 28, 2005**, in Courtroom 5, United States District Court for the Southern District of Florida, 301 North Miami Avenue, 5th Floor, Miami, Florida 33128, before the Honorable Patricia A. Seitz, on the proposed Settlement and applications for fees and costs and for incentive awards to the Consumer and TPP Plaintiffs. To learn whether the hearing has been postponed, please visit the website at www.TerazosinLitigation.com or call the Settlement Administrator at 1-877-886-0283.

To claim money from the Settlement, you need to complete either the TPP Claim Form or Consumer Claim Form that is provided with the full Notice and mail the Claim Form **postmarked no later than July 15, 2005**, to the Settlement Administrator at: **In re Terazosin Hydrochloride Antitrust Litigation, c/o Complete Claim Solutions, Inc., P.O. Box 24607, West Palm Beach, FL 33416.** (If you elect to exclude yourself from the Settlement classes, you may not file a Claim Form and will not be entitled to any money from this Settlement.)

To obtain the full Notice, a Claim Form, or more information, you may write the Settlement Administrator at the address above, call toll-free at 1-877-886-0283, or visit the website at www.TerazosinLitigation.com.

PLEASE DO NOT CONTACT THE COURT FOR ADDITIONAL INFORMATION

Dated: March 7, 2005

BY ORDER OF THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF FLORIDA